Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $933,589.80 in Stock

Posted by Geri Gentry on Jun 28th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 3,410 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80. Following the completion of the transaction, the chief executive officer directly owned 1,610 shares of the company’s stock, valued at $440,785.80. The trade was a 67.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 1.7%

NASDAQ ONC opened at $279.89 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $239.25 and a 12-month high of $385.22. The company has a fifty day simple moving average of $291.75 and a two-hundred day simple moving average of $310.21. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock has a market cap of $30.71 billion, a P/E ratio of 62.62 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. On average, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of the stock. Bank of America Corp DE acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at about $67,657,000. Man Group plc acquired a new stake in BeOne Medicines during the second quarter worth about $59,031,000. Capital International Investors grew its holdings in BeOne Medicines by 3.3% during the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after acquiring an additional 161,052 shares during the period. BNP Paribas Financial Markets purchased a new position in BeOne Medicines during the second quarter valued at approximately $38,337,000. Finally, First Trust Advisors LP raised its position in BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wolfe Research started coverage on BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective on the stock. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Sunday. Jefferies Financial Group lowered BeOne Medicines from a “buy” rating to a “hold” rating and dropped their target price for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target on the stock. Finally, Leerink Partners lifted their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

View Our Latest Research Report on BeOne Medicines

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.